JGC
OLMA icon

J. Goldman & Co’s Olema Pharmaceuticals OLMA Stock Holding History

J. Goldman & Co’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,500
Closed -$132K – 689
2025
Q3 		$132K Hold
13,500
– – ﹤0.01% 425
2025
Q2 		$57.5K Hold
13,500
– – ﹤0.01% 430
2025
Q1 		$50.8K Hold
13,500
– – ﹤0.01% 455
2024
Q4 		$78.7K Sell
13,500
-20,250
-60% -$202K ﹤0.01% 423
2024
Q3 		$403K Buy
+33,750
New +$431K 0.01% 367
2024
Q1 		– Sell
-50,766
Closed -$655K – 491
2023
Q4 		$712K Buy
50,766
+19,434
+62% +$261K 0.03% 250
2023
Q3 		$387K Sell
31,332
-77,058
-71% -$785K 0.01% 296
2023
Q2 		$979K Sell
108,390
-338,693
-76% -$2.04M 0.04% 253
2023
Q1 		$1.55M Sell
447,083
-68,494
-13% -$279K 0.06% 220
2022
Q4 		$1.26M Buy
+515,577
New +$1.5M 0.06% 206

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

J. Goldman & Co's OLMA Position: Q4 2025 in Review

J. Goldman & Co sold out of Olema Pharmaceuticals (OLMA) in Q4 2025, closing a stake of 13,500 shares — an estimated $132K sold.

J. Goldman & Co first reported a position in OLMA in Q4 2022 and held it in 10 quarters. The position peaked at $1.55M in Q1 2023. 200 funds tracked by Wall St. Rank hold OLMA as of Q4 2025.

  • J. Goldman & Co reported no remaining Olema Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 13,500 Olema Pharmaceuticals shares in Q4 2025, an estimated $132K.
  • J. Goldman & Co first reported a position in Olema Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • J. Goldman & Co's Olema Pharmaceuticals position peaked at $1.55M in Q1 2023.
  • 200 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.